Advagene Biopharma Co (ROCO:6709) Short-Term Capital Lease Obligation : NT$0.18 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Short-Term Capital Lease Obligation?

Advagene Biopharma Co's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$0.18 Mil.

Advagene Biopharma Co's quarterly Short-Term Capital Lease Obligation increased from Jun. 2022 (NT$0.46 Mil) to Dec. 2022 (NT$1.35 Mil) but then declined from Dec. 2022 (NT$1.35 Mil) to Jun. 2023 (NT$0.18 Mil).

Advagene Biopharma Co's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (NT$1.27 Mil) to Dec. 2022 (NT$1.35 Mil) but then declined from Dec. 2022 (NT$1.35 Mil) to Dec. 2023 (NT$0.00 Mil).

Advagene Biopharma Co Short-Term Capital Lease Obligation Historical Data

The historical data trend for Advagene Biopharma Co's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Short-Term Capital Lease Obligation Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.23

1.27

1.35

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial										1.27	0.46	1.35	0.18	-

Advagene Biopharma Co Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Advagene Biopharma Co Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines